Stelexis Therapeutics
Jason Fuller, Ph.D., is a Partner on the Biotherapeutics group at Deerfield and joined the Firm in 2021. Prior to Deerfield, Dr. Fuller was an investor at New Enterprise Associates (NEA), where he co-managed several investments in therapeutics, as well as in tools and diagnostics. Previous to NEA, he served as Head of Corporate Development at Jounce Therapeutics, one of several company formation projects he helped initiate in his role as Principal at Third Rock Ventures before joining Jounce. Dr. Fuller holds a B.S. in Chemical Engineering from Michigan State University, an M.Phil. from Cambridge University, and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology, where he completed his degree in the lab of Robert Langer.
This person is not in the org chart
This person is not in any teams
Stelexis Therapeutics
Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs.